832-497-2220 [email protected]

Cell and Gene Therapy Challenge

Background Information

In recent years, the cell gene therapy industry has entered a period of rapid development on a global scale. It is estimated that by 2025, the FDA will approve 10 to 20 cell and gene therapy products for marketing each year.

The overall enthusiasm of China’s related medical fields has always been no less than that of the rest of the world. With the introduction of new policies, the emergence of innovative gene therapy companies, an influx of capital and support, and with the continued increase of scientific research investment and the strengthening of technology, clinical research of cell and gene therapy in China is increasing year by year. Currently it is second only to the United States. China has become one of the most active areas in the world for cell therapy clinical research.

In order to further promote the development of China’s biopharmaceutical industry, the “MyBioGate Global Innovation Challenge-Gene and Cell Therapy” will focus on the needs of the Chinese market as well as the development needs of enterprises and professional parks by recruiting innovative projects and teams from around the world. With the help of the project selection, roadshow docking and cross-border acceleration mechanisms of the MyBioGate Global Challenge, we will assist Chinese industrial parks, investment institutions and enterprises, to efficiently connect and interact with global preferred projects to achieve landing of new companies in China.

Project focus

Focus on soliciting genetically engineered drugs, gene therapy, immune cell therapy represented by CAR-T therapy, stem cell therapy, gene testing, gene editing, and so forth.

Cell and Gene Therapy

Cell and gene therapy (CGT) is playing a more important role in the pharmaceutical ecosystem as next-generation therapies to target intractable and genetic disease are developed. In 2019 alone, 27 cell and gene therapy products were launched worldwide; it is projected to grow to a market share of over US$11.96 billion by 2025. Ranking second worldwide, CGT in China is booming as more than 1000 clinical trials are undergoing, with thousands of patents approved. Between 2017 and 2019, 45 Chinese companies, 4 with international partnerships, were engaged in this field. Based on these data, it is likely that the CGT market will continue to grow. The Chinese government is now taking the lead to clarify regulation for CGT candidates in clinical trials and to also establish industrial regulations on technical manufacturing and quality standards. Global collaboration with multicenter clinical studies and government-driven IP innovation is expected to further drive China’s CGT market to deliver promising medication and treatments.

Submitted Projects:

Project ID: CGT100

Category: Cell and Gene Therapy Challenge

Keyword: ACE2 Inhibitor

Project/Product Summary:

Our apelin therapy provides the evolutionary solution to inhibit viral replication and downstream ACE2 downregulation at the receptor level.

Indications: Heart failure, diabetes, pulmonary hypertension

Stage: IND

Partnering Objective: Fundraising, Co-development

Country: USA

Project ID: CGT101

Category: Cell and Gene Therapy Challenge

Tumor infiltrating lymphocyte immunotherapy (TIL therapy)

Project/Product Summary:

Project relies on the Cancer Research Center of the Champalimaud Foundation of Portugal as the European clinical base. The introduction of immunological medical technology to the country, the first batch of European top tumor immunotherapy technologies, including tumor infiltrating T lymphocyte therapy, virus infection T cell therapy, etc.

Indications: Cancer, Tumor

Stage: Research

Partnering Objective: Fundraising, Co-development

Country: Portugal/China

Project ID: CGT102

Category: Cell and Gene Therapy Challenge

Brain repair technology

Project/Product Summary:

Project is developing a revolutionary brain repair technology for neurological diseases. Our proprietary and patented in vivo cell conversion technology regenerates neurons from glial cells in diseased central nervous system.

Company is developing two platform technologies, gene therapy and small molecule therapy, including 4 gene therapies and one small molecule in the pipeline, to treat a variety of neurological disorders including stroke, Alzheimer’s disease, ALS, spinal cord injury, Parkinson’s disease, and Huntington’s disease.

Indications: Stroke, Alzheimer’s disease, ALS, spinal cord injury, Parkinson’s disease and Huntington’s disease.

Stage: Preclinical

Partnering Objective: Fundraising, Co-development, Commercialization Licensing

Country: USA